This Phase 2 trial looked at whether a single intravenous dose of iron isomaltoside could improve exercise capacity in people with severe aortic stenosis and iron deficiency. The study took place at Oslo University Hospital and included 149 participants. Patients were randomly assigned to receive either the iron medication or a matching placebo, and neither the patients nor the researchers knew who received which during the trial.
The primary outcome measured was performance on a submaximal exercise test. Safety was monitored closely, and no adverse events, serious adverse events, discontinuations, or tolerability issues were reported during the 25.1-month follow-up period. However, because this was a small, early-phase study, the results are not yet definitive.
Readers should understand that this trial provides initial safety data but does not confirm long-term benefits or clinical effectiveness. More research is needed before doctors can recommend this treatment for routine use in patients with these conditions.